Ieq Capital LLC Buys 93,267 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Ieq Capital LLC boosted its stake in BioCryst Pharmaceuticals by 316.8% during the first quarter, now owning approximately 122,703 shares valued at around $920,000.
• BioCryst Pharmaceuticals recently reported quarterly earnings of $0.15 EPS, exceeding analysts' expectations and showing a 49.5% increase in revenue year-over-year.
• Analysts have set a consensus rating of "Moderate Buy" for BioCryst Pharmaceuticals, with an average price target of $16.70.

Ieq Capital LLC increased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 316.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 122,703 shares of the biotechnology company's stock after purchasing an additional 93,267 shares during the quarter. Ieq Capital LLC owned approximately 0.06% of BioCryst Pharmaceuticals worth $920,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BCRX. Nuveen LLC purchased a new position in BioCryst Pharmaceuticals in the first quarter valued at about $10,677,000. Jupiter Asset Management Ltd. raised its position in shares of BioCryst Pharmaceuticals by 82.4% in the first quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company's stock valued at $16,117,000 after purchasing an additional 971,040 shares during the period. Balyasny Asset Management L.P. bought a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $3,983,000. Woodline Partners LP bought a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $3,385,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of BioCryst Pharmaceuticals by 64.5% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,042,424 shares of the biotechnology company's stock valued at $7,818,000 after purchasing an additional 408,560 shares during the period. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Price Performance

BCRX traded down $0.16 during trading on Monday, hitting $8.12. 251,190 shares of the stock traded hands, compared to its average volume of 3,693,638. The firm has a market capitalization of $1.70 billion, a P/E ratio of -45.36, a price-to-earnings-growth ratio of 1.88 and a beta of 1.13. The firm has a 50-day moving average of $8.52 and a 200 day moving average of $8.75. BioCryst Pharmaceuticals, Inc. has a 12-month low of $6.01 and a 12-month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.12. The business had revenue of $163.35 million for the quarter, compared to analysts' expectations of $149.59 million. During the same period last year, the business earned ($0.06) earnings per share. The company's revenue was up 49.5% on a year-over-year basis. As a group, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on BCRX. Wedbush boosted their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research report on Monday, June 30th. Needham & Company LLC reissued a "buy" rating and issued a $17.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, August 4th. Bank of America boosted their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Tuesday, July 1st. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 26th. Finally, Royal Bank Of Canada reissued an "outperform" rating and issued a $13.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $16.70.

Insider Transactions at BioCryst Pharmaceuticals

In related news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the transaction, the director directly owned 65,352 shares of the company's stock, valued at $556,145.52. This trade represents a 51.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.10% of the stock is currently owned by company insiders.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.